Sinovac Biotech Ltd (SVA) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Sinovac Biotech Ltd  (NASDAQ: SVA)

Sinovac Biotech Ltd's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Sinovac Biotech Ltd in the fourth quarter 2025?
Sinovac Biotech Ltd recorded a cumulative net loss of $-199 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -3.11%.

Within the Major Pharmaceutical Preparations industry 81 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 2454 to 2742.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change -22.58 % -37.86 % -37.86 % -37.86 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -199 41 41 41 41
Return On Equity (TTM) -3.11 % 0.59 % 0.52 % 0.46 % 0.42 %
SVA's Total Ranking # 2742 # 2454 # # #
Equity (TTM) in Millions 6,396 6,396 6,396 6,396 8,262
Seq. Equity Change 0 % 0 % 0 % -22.58 % -19.73 %
Seq. Net Income Change - - - - -

Back to SVA Management Effectiveness >> SVA's 5 Years Annual ROE >> Compare SVA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 82
Sector # 234
Overall # 2742

Return On Equity Statistics
High Average Low
104.2 %
15.22 %
-3.11 %
(Dec 31 2021)   (Dec 31 2025)





SVA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 6,396 8,262 8,316 8,491 8,995
Y / Y Equity Change -22.58 % -0.64 % -2.06 % -5.61 % 695.13 %
Net Income in Millions -199 41 -121 -60 14,120
Y / Y Net Income Change - - - - 7524.93 %
Return On Equity -3.11 % 0.49 % -1.45 % -0.71 % 156.97 %

Back to SVA Management Effectiveness >> SVA's 5 Years Annual ROE >> Compare SVA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SVA's' Return on Equity at Yahoo Finance
SVA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SVA's Competitors
Subscribers only: Roe for Sinovac Biotech Ltd's Suppliers
Subscribers only: Return On Equity for SVA's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE

Date modified: 2026-09-16T10:47:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.